Enfusion (NYSE:ENFN) Shares Down 2.6%

Enfusion, Inc. (NYSE:ENFN)’s stock price dropped 2.6% during trading on Wednesday . The company traded as low as $8.39 and last traded at $8.50. Approximately 211,459 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 371,238 shares. The stock had previously closed at $8.73.

Enfusion Stock Down 3.6 %

The company has a market cap of $1.08 billion, a P/E ratio of 291.00, a price-to-earnings-growth ratio of 2.23 and a beta of 0.90. The stock’s 50-day moving average price is $8.52 and its 200 day moving average price is $8.87.

Enfusion (NYSE:ENFN) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Enfusion had a net margin of 1.98% and a return on equity of 6.17%. The firm had revenue of $49.46 million during the quarter, compared to the consensus estimate of $50.27 million. Analysts expect that Enfusion, Inc. will post 0.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Bronwen Bastone sold 18,241 shares of the business’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total transaction of $147,934.51. Following the transaction, the insider now owns 198,913 shares of the company’s stock, valued at $1,613,184.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 36.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enfusion

A number of institutional investors have recently bought and sold shares of ENFN. Brown Capital Management LLC boosted its stake in Enfusion by 6.5% during the fourth quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock worth $114,631,000 after buying an additional 724,502 shares in the last quarter. Scalar Gauge Management LLC acquired a new stake in shares of Enfusion in the 4th quarter valued at $1,993,000. Wasatch Advisors LP boosted its stake in shares of Enfusion by 34.2% in the 1st quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock valued at $7,327,000 after purchasing an additional 201,771 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Enfusion during the 2nd quarter worth about $683,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.